Triple Therapy for Advanced Kidney Cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of three drugs—sasanlimab (immunotherapy), palbociclib (targeted therapy), and axitinib (VEGF inhibitor)—for people with advanced kidney cancer who have not had prior treatment. It aims to see if this triple therapy is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic kidney cancer (clear cell type or certain translocation type) that cannot be removed surgically.
- You have not had any prior treatment for advanced kidney cancer (no prior immunotherapy, targeted therapy, or CDK4/6 inhibitor).
- Your cancer is measurable on scans (RECIST 1.1).
- You are 18 or older, able to swallow pills, and have good organ function (kidney, liver, blood counts).
- You must not have untreated brain metastases, active autoimmune disease, or certain heart or lung problems.
- You agree to use effective contraception if applicable, and can provide a recent tumor tissue sample (biopsy or block).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs — an immunotherapy (toripalimab) and a targeted therapy (axitinib) — as the first treatment for advanced kidney cancer. The approach may shrink the tumor before deciding whether and when to remove the kidney surgically.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
This trial tests a new combination of two oral drugs (abemaciclib and cabozantinib) for people with advanced kidney cancer (clear cell type) who have already tried at least two other treatments, including an immunotherapy and a targeted therapy, but their cancer kept growing. The goal is to see if this combination can shrink tumors or slow the cancer.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
This trial tests a combination of two drugs—an immunotherapy called toripalimab and a targeted therapy called axitinib—for people with rare kidney cancers that have spread. The goal is to see if this combination can shrink or control the cancer before any surgery to remove the kidney.
Hear when a new Metastatic Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.